Botensilimab
- Generic Name
- Botensilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408310-37-0
- Unique Ingredient Identifier
- 1Z5YC3ME5N
- Background
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
- Conditions
- Colorectal Cancer (CRC)Pancreatic CancerNon-Small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)MelanomaSarcomaOvarian CancerProstate Cancer
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT06751524
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Phase 2
Recruiting
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Michael B. Atkins, MD
- Target Recruit Count
- 120
- Registration Number
- NCT05928806
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath